TrialPloS one2014

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.

Sue Sha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.